Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial
文献类型：期刊论文
| 作者 | Shi, Hui7; Xu, Jing6; Lang, Xiaoe5; Wu, Hanjing Emily4; Xiu, Mei Hong3; Zhang, Xiang Yang1,2 |
| 刊名 | FRONTIERS IN PHARMACOLOGY
 |
| 出版日期 | 2022-04-26 |
| 卷号 | 13页码:10 |
| 关键词 | treatment-resistant ziprasidone sertraline efficacy schizophrenia acute exacerbation |
| DOI | 10.3389/fphar.2022.863588 |
| 通讯作者 | Xiu, Mei Hong(xiumeihong97@gmail.com) ; Zhang, Xiang Yang(zhangxy9@gmail.com) |
| 英文摘要 | Treatment-resistant schizophrenia (TRS) is a prevalent clinical problem with heterogeneous presentations. However, the clinical trial designs for new treatments are still lacking. This study aimed to assess the efficacy of ziprasidone plus sertraline in TRS patients as compared to ziprasidone monotherapy. We conducted a 24 weeks, randomized, controlled, double-blinded clinical research trial. 62 treatment-resistant patients with acute exacerbation SZ were randomly allocated to receive a usual dose of ziprasidone (120-160 mg/d) monotherapy (Control group) and 53 TRS inpatients were to receive a low dose of ziprasidone (60-80 mg/d) in combination with sertraline (ZS group). Treatment outcomes were measured by the Positive and Negative Syndrome Scale (PANSS), the Hamilton Depression Rating Scale (HAMD), CGI-Severity (CGI-S) and Personal and Social Performance Scale (PSP) at baseline, week 4, 8, 12, and 24. Relative to control group, the patients in ZS group showed greater reductions in the following: PANSS positive symptom, negative symptom, total score, and HAMD total score. Additionally, the patients in ZS group had a greater increase in PSP total score. Notably, the reduction in HAMD was positively correlated with the reduction in PANSS total score. The reduction in CGI-S was a predictor for the improvement of psychosocial functioning in patients. Furthermore, the ZS group had a lower rate of side effects compared to the control group. Our findings suggest that a low dose of ziprasidone in combination with sertraline is an effective therapy for the clinical symptoms as compared to a usual dose of ziprasidone in the treatment-resistant patients with acute exacerbation SZ. |
| 收录类别 | SCI |
| WOS关键词 | NEGATIVE SYNDROME SCALE ; ANTIPSYCHOTIC-DRUGS ; DOUBLE-BLIND ; OLANZAPINE ; CLOZAPINE ; TOLERABILITY ; ANTIDEPRESSANTS ; ACCEPTABILITY ; RISPERIDONE ; DOPAMINE |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | FRONTIERS MEDIA SA |
| WOS记录号 | WOS:000795153000001 |
| 源URL | [http://ir.psych.ac.cn/handle/311026/42709]  |
| 专题 | 心理研究所_中国科学院心理健康重点实验室 |
| 通讯作者 | Xiu, Mei Hong; Zhang, Xiang Yang |
| 作者单位 | 1.Univ Chinese Acad Sci, Dept Psychol, Beijing, Peoples R China 2.Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China 3.Peking Univ, Beijing HuiLongGuan Hosp, HuiLongGuan Clin Med Sch, Beijing, Peoples R China 4.Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX USA 5.Shanxii Med Univ, Dept Psychiat, Taiyuan, Peoples R China 6.Qingdao Med Univ, Qingdao Mental Hlth Ctr, Qingdao, Peoples R China 7.Capital Med Univ, Beijing Chao Yang Hosp, Dept Psychiat, Beijing, Peoples R China |
| 推荐引用方式 GB/T 7714 |
Shi, Hui,Xu, Jing,Lang, Xiaoe,et al. Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial [J]. FRONTIERS IN PHARMACOLOGY,2022,13:10. |
| APA |
Shi, Hui,Xu, Jing,Lang, Xiaoe,Wu, Hanjing Emily,Xiu, Mei Hong,&Zhang, Xiang Yang.(2022). Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial .FRONTIERS IN PHARMACOLOGY,13,10. |
| MLA |
Shi, Hui,et al." Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial ".FRONTIERS IN PHARMACOLOGY 13(2022):10. |
入库方式： OAI收割
来源：心理研究所
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。